Brihatyadi Kashayam: Benefits, Evidence & Safety

TL;DR

Brihatyadi Kashayam is a classical Ayurvedic herbal decoction for urinary disorders such as painful urination, urinary infections, and kidney stones. Its five ingredients, Brihati, Kantakari, Shalparni, Prishnaparni, and Gokshura, are traditional diuretics. Modern evidence is limited to animal and laboratory studies; no human trials of the formulation exist.

What it is

Brihatyadi Kashayam (also spelled Brihathyadi or Bruhathyadi; "kashayam" is the Kerala term for kwath, a water decoction) is a classical polyherbal Ayurvedic medicine sold as a ready-made liquid, a powder (churna), and tablets (formulation overview). The standard recipe combines five herbs in equal parts: the group known as Laghu Panchamula, the first five drugs of the ten-herb Dashamula set: Brihati (Solanum indicum; Kerala manufacturers such as Kottakkal list Solanum anguivi), Kantakari (Solanum xanthocarpum, also given as S. virginianum), Shalparni (Desmodium gangeticum), Prishnaparni (Uraria picta), and Gokshura (Tribulus terrestris) (ingredients and parts; Kottakkal label). Like all kwaths, it is prepared by boiling the herbs in water until the liquid reduces (preparation method).

Check the label: recipes vary. Some manufacturers replace Kantakari with Bhadra (Aerva lanata) (AVN tablet ingredients), and Kottakkal lists Pseudarthria viscida under the name Salaparni (Kottakkal label). A different formula altogether, Brihati, Prishnaparni, Kutaja, Paata, and Yashtimadhu, is described in the Yogarathnakara for difficult urination and was the version tested in a 2020 animal study of kidney protection (Binu et al., IJAPR 2020). "Brihatyadi Kashayam" on a bottle may therefore mean more than one recipe.

Traditional use

Ayurvedic practitioners cite the Ashtanga Hridayam, Chikitsa Sthana, in the chapter on urinary obstruction disorders (Mutraghata, 11/35), as the classical source of this decoction (classical reference; textual source). Traditionally it is used for disorders of the urinary channel, painful or difficult urination (mutrakricchra/dysuria), urinary tract infections, bladder inflammation (cystitis), and urinary calculi (kidney stones), with manufacturers listing dysuria, urinary tract infection, and renal calculi among its indications (traditional indications; Kottakkal label). The Yogarathnakara variant is described for mootrakrichra and is said to act through its diuretic (mutrala) property (Binu et al., IJAPR 2020). All of this is traditional use, not clinically proven effect.

What modern research says

No randomized or controlled human trial of Brihatyadi Kashayam, for urinary infections, stones, or any other indication, was found. The evidence below is preclinical or anecdotal.

Kidney protection in rats (a version of the formulation)

In a 2020 animal study, the Yogarathnakara version of Brihathyadi Kashayam (Brihati, Prishnaparni, Kutaja, Paata, Yashtimadhu) was given to rats with rifampicin-induced kidney damage: the higher dose significantly lowered serum creatinine, urea, and uric acid, increased urine output, and reversed degenerative changes in the kidney's nephrons compared with untreated rats (animal study) (Binu et al., IJAPR 2020). Because this tested a different five-herb recipe, the result cannot be transferred directly to the standard Laghu Panchamula version.

Diuretic activity (Gokshura, the lead ingredient)

In a 2003 study, an aqueous extract of Tribulus terrestris leaves and fruits at an oral dose of 5 g/kg produced a positive diuresis in Wistar rats that was slightly greater than that of furosemide, with markedly increased urinary sodium, potassium, and chloride. It also caused contractile activity in isolated guinea-pig ileum (animal and in-vitro study) (Al-Ali et al., J Ethnopharmacol 2003: PubMed). The authors noted the plant's long empirical use to propel urinary stones and concluded it merits further pharmacological study: a plausibility signal for the decoction's traditional diuretic use, not proof of efficacy.

Anti-stone activity in the lab (Gokshura)

An aqueous extract of T. terrestris fruit inhibited the nucleation and growth of calcium oxalate crystals in a concentration-dependent manner, and protected NRK 52E kidney epithelial cells from oxalate-induced injury, raising cell viability and lowering injury markers dose-dependently (in-vitro study) (Aggarwal et al., Int Braz J Urol 2010). The authors proposed it as a potential candidate for phytotherapy against urolithiasis: early laboratory evidence only.

Case reports

A published Ayurvedic case report described a 66-year-old man with a single renal calculus treated with a multi-drug regimen including Brihatyadi Kashayam 15 ml, with encouraging results: but a single patient on several drugs proves nothing about the kashayam itself (AyurLog case report). A 2026 case report on chronic cystitis (mutrakrichha) reported symptomatic relief with an Ayurvedic protocol that included Bruhatyadi Kashaya alongside other herbs (IJCRT case report). Case reports are the weakest form of evidence and cannot establish that the formulation works.

Safety & contraindications

There are no human safety trials of Brihatyadi Kashayam itself, so its safety profile as a medicine is unestablished. For its key ingredient Gokshura (Tribulus terrestris), the picture is mixed: a systematic review of five randomized trials (279 participants) found no serious adverse events with short-term use, though the evidence certainty was rated very low (systematic review: PubMed). On the other hand, a clinical review documents two reports of severe kidney injury (acute tubular necrosis) in young men with no prior kidney disease linked to Tribulus supplements, and flags possible CYP450-mediated drug interactions (supplement harms review: PMC). European regulators note kidney effects in animals after chronic consumption of large amounts of the herb and say the data are very limited (EMA/HMPC assessment report, 2022).

Practical cautions: avoid in pregnancy and breastfeeding, no human safety data exist, and consult a qualified practitioner first if you take diuretics, blood-pressure, or diabetes medicines, since the rat study showed increased urinary electrolyte loss (Al-Ali et al., 2003). Sellers sometimes advertise the kashayam as having "no side effects" (seller claim), but no clinical safety study backs that claim.

Importantly, bacterial urinary infections are treated with antibiotics, and an untreated UTI can spread to the kidneys or bloodstream (St George's NHS UTI leaflet). If you have burning urination with fever, back pain, or blood in the urine, see a clinician promptly rather than relying on a herbal decoction.

FAQs

What is Brihatyadi Kashayam used for?

In Ayurvedic practice it is used for urinary disorders: painful or difficult urination (dysuria), urinary tract infections, bladder inflammation (cystitis), and kidney stones. Kottakkal Arya Vaidya Sala lists dysuria, urinary tract infection, and renal calculi as its indications (label). These are traditional uses; no human clinical trial has confirmed they work.

What are the ingredients of Brihatyadi Kashayam?

The standard recipe combines five herbs in equal parts: Brihati (Solanum indicum), Kantakari (Solanum xanthocarpum), Shalparni (Desmodium gangeticum), Prishnaparni (Uraria picta), and Gokshura (Tribulus terrestris) (overview). Some manufacturers swap Kantakari for Bhadra (Aerva lanata) or list different botanical sources, so check the label (AVN ingredients).

Does Brihatyadi Kashayam dissolve kidney stones?

There is no human trial showing it dissolves kidney stones. In laboratory tests, an aqueous extract of its Gokshura fruit inhibited calcium oxalate crystal growth and protected kidney cells from oxalate injury (Aggarwal et al., 2010). A published case report of a single kidney stone used it within a multi-drug regimen (AyurLog). These are early findings, not proof it works in people.

Can it replace antibiotics for a UTI?

No. No clinical trial has tested Brihatyadi Kashayam against bacterial urinary infections, and antibiotics remain the standard treatment: untreated UTIs can spread to the kidneys or bloodstream (NHS leaflet). If you have burning urination, fever, or back pain, see a clinician promptly rather than relying on a herbal decoction.

How is Brihatyadi Kashayam taken?

Commercial bottles are typically labelled 10–15 ml for adults (5–10 ml for children), diluted in three times lukewarm water and taken twice daily before food (label). That is the manufacturer's label, not a clinically tested dose: there is no established medicinal dose, so follow a qualified practitioner's guidance.

Is it safe in pregnancy or while breastfeeding?

There are no human safety studies of Brihatyadi Kashayam, or of its key ingredient Gokshura, in pregnancy or breastfeeding. One Ayurvedic seller advises consulting a physician before use in pregnancy (seller page). The safest course is to avoid it unless a qualified clinician familiar with your pregnancy advises otherwise.

Are there side effects or drug interactions?

No formal safety trial of the formulation exists. Short-term Tribulus trials reported no serious adverse events (systematic review), but two case reports link Tribulus supplements to severe kidney injury, and a clinical review flags possible CYP450 drug interactions (harms review). Tell your doctor about all herbs you take, especially with diuretics, blood-pressure, or diabetes medicines.

How is it different from Varunadi Kashayam?

Both are classical urinary decoctions, but their cores differ: Brihatyadi Kashayam is built on the five Laghu Panchamula herbs with Gokshura as the diuretic anchor, while Varunadi Kashayam is a 16-herb formula led by Varuna (Crataeva nurvala) ([our Varunadi Kashayam article](/learn/herbs/varunadi-kashayam)). A practitioner chooses between them based on the condition being treated.

Sources

Tier 1 (peer-reviewed journals, regulatory assessments):

Tier 2 (clinical case reports, manufacturer labels):

Tier 3 (secondary references):

This article is for educational purposes only and is not medical advice. Consult a qualified practitioner before using any Ayurvedic formulation.